Treatment for young patients with relapsed or refractory brain tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and effectiveness of a treatment involving super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients under 22 years old who have relapsed or refractory intracranial gliomas. The treatment aims to deliver medication directly to the tumor site to improve outcomes. Participants must have a confirmed diagnosis of specific types of gliomas and meet certain health criteria to ensure safety during the treatment process.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Documented histologic diagnosis of relapsed or refractory glioblastoma multiforme (GBM), anaplastic astrocytoma (AA), fibrillary astrocytomas (FA), pilomyxoid astrocytoma (PXA), oligodendroglioma, or anaplastic mixed oligoastrocytoma (AOA), or radiologically diagnosed diffuse intrinsic brainstem glioma (DIPG)
* Must have at least one confirmed and evaluable tumor site
* Must have a Karnofsky or Lansky performance status ≥60%.
* No chemotherapy for three weeks prior to treatment
* Patients must have adequate hematologic reserve with absolute neutrophils≥1000/mm3 and platelets ≥100,000/ mm3
* Pre-enrollment chemistry parameters must show: bilirubin\<1.5x the institutional upper limit of normal (IUNL); Aspartate Aminotransferase( AST) or Alanine transaminase (ALT)\<2.5x IUNL and creatinine\<1.5x IUNL
* Pre-enrollment coagulation parameters (PT and PTT) must be ≤1.5x the IUNL
* Growth factor(s): Must not have received within 1 week of entry onto this study
* Steroids: Systemic corticosteroid therapy is permissible in patients with Central Nervous System (CNS) tumors for treatment of increased intracranial pressure or symptomatic tumor edema. Patients with CNS tumors who are receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to study entry.
* Patients of reproductive age must agree to use a medically effective method of contraception during and for a period of three months after the treatment period. A pregnancy test will be performed on each premenopausal female of childbearing potential immediately prior to entry into the research study
* Patients or their parents/guardians must be able to understand and give written informed consent. Informed consent must be obtained at the time of patient screening
* Because of known concerns with Avastin and wound healing, craniotomy patients are eligible for the treatment if they have had a craniotomy greater than two weeks prior to Intra-Arterial (IA) therapy. Craniotomy or major procedure after SIACI Avastin therapy should wait 4 weeks. Minor surgeries may be performed after two weeks

Exclusion Criteria:

* Females who are pregnant or lactating
* Females of childbearing potential and fertile men will be informed as to the potential risk of procreation while participating in this research trial and will be advised that they must use effective contraception during and for a period of three months after the treatment period. If they do not agree, they will be ineligible for the study
* Patients with significant concurrent medical or psychiatric conditions that would place them at increased risk or affect their ability to receive or comply with treatment or post-treatment clinical monitoring

Where it's running

• Jackson Memorial Hospital
  Miami, Florida, United States Recruiting

Study contacts

• Principal investigator: Heather McCrea, MD — University of Miami
• Study coordinator: Heather McCrea, MD
• Email: hmccrea@med.miami.edu
• Phone: 305-585-3627

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lorlatinib for newly diagnosed high-grade glioma with ALK or ROS1 fusions

  This trial will test whether the oral medicine lorlatinib helps children and young adults (ages 1–21) with newly diagnosed high-grade gliomas that have ALK or ROS1 fusions, given alone, with chemotherapy, or after radiation.

  Recruiting at 2 sites Early Phase 1 Nationwide Children's Hospital · Aurora, Colorado and 17 other locations · NCT06333899

• Combining ribociclib and everolimus for treating high-grade gliomas in young patients

  This study is testing if a combination of two drugs, ribociclib and everolimus, can help young patients with high-grade gliomas live longer and feel better after their initial treatment.

  Recruiting at 12 sites Phase 2 Nationwide Children's Hospital · Aurora, Colorado and 19 other locations · NCT05843253

• Genetic profiling for pediatric high-grade glioma treatment eligibility

  This study is testing if genetic testing of brain tumors in children and young adults with high-grade gliomas can help match them to the best treatment options.

  Recruiting at 13 sites Nationwide Children's Hospital · Aurora, Colorado and 21 other locations · NCT05839379

• Using targeted delivery of Bevacizumab for treating recurrent brain tumors

  This study is testing a new way to deliver the cancer drug Bevacizumab directly to the brain to see if it helps people with recurrent brain tumors live longer and feel better compared to the usual method of giving it through an IV.

  Recruiting Phase 1/2 Northwell Health · New York, New York · NCT01269853

• Petosemtamab plus chemotherapy vs standard chemo plus cetuximab or bevacizumab in RAS/BRAF WT colorectal cancer

  This phase 3 trial tests whether adding petosemtamab to standard chemotherapy works better than the usual chemo plus cetuximab or bevacizumab for people with recurrent, unresectable, or metastatic colorectal cancer that is KRAS/NRAS/BRAF wild type.

  Recruiting at 5 sites Phase 3 Genmab · Hot Springs, Arkansas and 4 other locations · NCT07775287

• Bevacizumab, sintilimab, cetuximab and irinotecan in refractory RAS wild-type metastatic colorectal cancer

  This trial tests whether adding sintilimab to a cetuximab and irinotecan backbone, with or without bevacizumab, helps patients with heavily pretreated metastatic colorectal cancer that has RAS wild-type tumors.

  Recruiting Phase 2 Guangdong Provincial People's Hospital · Guangzhou, Guangdong · NCT07722754

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.